Bologna-based Cellply raises €7.15 million to advance tools for faster immunotherapy and cell therapy development

Read also - German NanoStruct Secures €2.6M Seed Funding To Speed Up Harmful Bacteria Detection In Food

The investment round was led by ENEA Tech e Biomedical, with further support from existing shareholders, including the SAFE conversion into equity by CDP Venture Capital through its Fondo Rilancio initiative. According to the company, a small final portion of the funding round is still open and available for selected investors.

Alessia Zanelli, President and CEO at Cellply, said, “This investment provides the resources to accelerate our commercial expansion and advance innovative quality control solutions that can help unlock broader adoption of ATMPs worldwide.”

Founded in 2013 by Massimo Bocchi and Roberto Guerrieri, Cellply is a biology-focused deep tech company developing advanced tools designed to support the rapid development of next-generation immunotherapies and cell-based therapies with improved potency and durability.

The company develops innovative solutions capable of characterising these promising therapeutic approaches at single-cell resolution. Its flagship platform, VivaCyte®, is an analytical system created for the discovery and process development of cell therapies.

VivaCyte allows researchers to characterise immune cells at an unprecedented level of resolution and scale through a fully automated workflow that ranges from sample preparation to image analysis.

To build VivaCyte®, the company combined patented microfluidic technology, AI-powered automated image analysis, comprehensive automation, and dedicated software into a single integrated platform.

Cellply intends to use the newly raised capital to accelerate the international expansion of its VivaCyte® platform and strengthen its commercial footprint across important global markets.

The funding will also support the advancement of next-generation automated functional testing solutions for ATMP quality control. Through these developments, the company aims to provide highly accurate cell potency assessments while simplifying and streamlining batch release processes.

About Cellply

Cellply is a biotechnology and DeepTech company based in Bologna that develops advanced tools for cancer immunotherapy and cell therapy research. Founded in 2013, the company helps biopharmaceutical companies and research organizations better understand how immune cells work by using single-cell analysis technology. Cellply is best known for its main platform, VivaCyte®, a fully automated system designed to study immune cells with high accuracy and efficiency. The platform combines patented microfluidic technology, AI-powered image analysis, robotics, and advanced software to support the research, development, and quality control of next-generation cell therapies.